{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:33:19Z","timestamp":1761129199110,"version":"3.32.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2002,11,1]],"date-time":"2002-11-01T00:00:00Z","timestamp":1036108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2002,11,1]],"date-time":"2002-11-01T00:00:00Z","timestamp":1036108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2002,11]]},"DOI":"10.1136\/ard.61.suppl_2.ii67","type":"journal-article","created":{"date-parts":[[2014,10,22]],"date-time":"2014-10-22T19:21:06Z","timestamp":1414005666000},"page":"ii67-ii69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"S2","title":["Infliximab treatment for rheumatic disease: clinical and radiological efficacy"],"prefix":"10.1016","volume":"61","author":[{"given":"E W","family":"St Clair","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ard.61.suppl_2.ii67_bib1","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/0161-5890(93)90106-L","article-title":"Construction and initial characterization of a mouse-human chimeric anti-TNF antibody","volume":"30","author":"Knight","year":"1993","journal-title":"Mol Immunol"},{"key":"10.1136\/ard.61.suppl_2.ii67_bib2","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/art.1780361206","article-title":"Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor \u03b1","volume":"36","author":"Elliott","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.61.suppl_2.ii67_bib3","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","article-title":"Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor \u03b1 (cA2) versus placebo in rheumatoid arthritis","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet"},{"key":"10.1136\/ard.61.suppl_2.ii67_bib4","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S0140-6736(94)90632-7","article-title":"Repeated therapy with monoclonal antibody to tumour necrosis factor \u03b1 (cA2) in patients with rheumatoid arthritis","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet"},{"key":"10.1136\/ard.61.suppl_2.ii67_bib5","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor \u03b1 monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.61.suppl_2.ii67_bib6","first-page":"841","article-title":"Chimeric anti-tumor necrosis factor-\u03b1 monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy","volume":"27","author":"Kavanaugh","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.61.suppl_2.ii67_bib7","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor \u03b1 monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1136\/ard.61.suppl_2.ii67_bib8","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"issue":"suppl","key":"10.1136\/ard.61.suppl_2.ii67_bib9","first-page":"S269","article-title":"102-wk clinical and radiologic results from the ATTRACT trial: A 2 year, randomized, controlled, phase 3 trial of infliximab (Remicade\u2122) in patients with active rheumatoid arthritis despite methotrexate","volume":"43","author":"Lipsky","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.61.suppl_2.ii67_bib10","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0950-3579(96)80043-4","article-title":"Plain X-rays in rheumatoid arthritis: overview of scoring methods, their reliability and applicability","volume":"10","author":"Van der Heijde","year":"1996","journal-title":"Baillieres Clin Rheumatol"},{"key":"10.1136\/ard.61.suppl_2.ii67_bib11","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/art.10302","article-title":"The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis. Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial","volume":"46","author":"St. Clair","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.61.suppl_2.ii67_bib12","first-page":"428","article-title":"Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor \u03b1 (infliximab) in spondyloarthropathy: an open pilot study","volume":"59","author":"Van den Bosch","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.61.suppl_2.ii67_bib13","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/ard.61.3.207","article-title":"Repeated infusions of infliximab, a chimeric anti-TNF\u03b1 antibody, in patients with active spondyloarthropathy: one year follow-up","volume":"61","author":"Kruithof","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.61.suppl_2.ii67_bib14","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/art.511","article-title":"Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor \u03b1 (infliximab) versus placebo in active spondyloarthropathy","volume":"46","author":"Van den Bosch","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.61.suppl_2.ii67_bib15","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E","article-title":"Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor \u03b1 monoclonal antibody infliximab","volume":"43","author":"Brandt","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.61.suppl_2.ii67_bib16","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"key":"10.1136\/ard.61.suppl_2.ii67_bib17","first-page":"2225","article-title":"Preliminary core sets for endpoints in ankylosing spondylitis","volume":"24","author":"Van der Heijde","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.61.suppl_2.ii67_bib18","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1365-2133.2001.04089.x","article-title":"Treatment of psoriatic arthritis with anti-tumor necrosis factor-\u03b1 antibody clears skin lesions of psoriasis resistant to treatment with methotrexate","volume":"144","author":"Oglivie","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1136\/ard.61.suppl_2.ii67_bib19","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"key":"10.1136\/ard.61.suppl_2.ii67_bib20","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724434729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724434729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.61.suppl_2.ii67","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T05:37:15Z","timestamp":1736141835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724434729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,11]]},"references-count":20,"alternative-id":["S0003496724434729"],"URL":"https:\/\/doi.org\/10.1136\/ard.61.suppl_2.ii67","relation":{},"ISSN":["0003-4967"],"issn-type":[{"type":"print","value":"0003-4967"}],"subject":[],"published":{"date-parts":[[2002,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infliximab treatment for rheumatic disease: clinical and radiological efficacy","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.61.suppl_2.ii67","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2002 Copyright 2002 by Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}